Anesthesia & Analgesia:
Patient Safety: Research Reports
Increased Long-Term Mortality After a High Perioperative Inspiratory Oxygen Fraction During Abdominal Surgery: Follow-Up of a Randomized Clinical Trial
Meyhoff, Christian S. MD, PhD*; Jorgensen, Lars N. MD, DMSc†; Wetterslev, Jørn MD, PhD‡; Christensen, Karl B. PhD§; Rasmussen, Lars S. MD, PhD, DMSc*; PROXI Trial Group
From the *Department of Anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; †Department of Surgery K, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark; ‡Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; and §Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
The PROXI trial has received funding from The Danish Medical Research Council (271–05-0206), the Lundbeck Foundation (402/06), Rigshospitalet's Research Council, the Novo Nordisk Foundation, the Aase and Ejnar Danielsens Foundation (105728), the A.P. Møller Foundation for the Advancement of Medical Science, the Danish Society of Anaesthesiology and Intensive Care Medicine's Research Initiative, the Beckett-Foundation, the Brødrene Hartmanns Foundation, and Etly and Jørgen Stjerngrens Foundation. None of the funding sources had influence on the trial design, data collection, data management, data analysis, or reporting.
The authors declare no conflicts of interest.
Reprints will not be available from the authors.
Address correspondence to Christian S. Meyhoff, MD, PhD, Department of Anaesthesia, section 4231, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Address e-mail to firstname.lastname@example.org.
Accepted June 11, 2012
Published ahead of print July 13, 2012
BACKGROUND: A high perioperative inspiratory oxygen fraction (80%) has been recommended to prevent postoperative wound infections. However, the most recent and one of the largest trials, the PROXI trial, found no reduction in surgical site infection, and 30-day mortality was higher in patients given 80% oxygen. In this follow-up study of the PROXI trial we assessed the association between long-term mortality and perioperative oxygen fraction in patients undergoing abdominal surgery.
METHODS: From October 8, 2006, to October 6, 2008, 1386 patients underwent elective or emergency laparotomy and were randomized to receive either 80% or 30% oxygen during and for 2 hours after surgery. The follow-up date was February 24, 2010. Survival was analyzed using Kaplan-Meier statistics and the Cox proportional hazards model.
RESULTS: Vital status was obtained in 1382 of 1386 patients after a median follow-up of 2.3 years (range 1.3 to 3.4 years). One hundred fifty-nine of 685 patients (23.2%) died in the 80% oxygen group compared to 128 of 701 patients (18.3%) assigned to 30% oxygen (HR, 1.30 [95% confidence interval, 1.03 to 1.64], P = 0.03). In patients undergoing cancer surgery, the HR was 1.45; 95% confidence interval, 1.10 to 1.90; P = 0.009; and after noncancer surgery, the HR was 1.06; 95% confidence interval, 0.69 to 1.65; P = 0.79.
CONCLUSIONS: Administration of 80% oxygen in the perioperative period was associated with significantly increased long-term mortality and this appeared to be statistically significant in patients undergoing cancer surgery but not in noncancer patients.
The impact of anesthetic management on long-term complications is increasingly recognized.1 One variable that can be optimized is the wound oxygen tension, which commonly is low in the perioperative phase.2 Wound oxygenation may be increased in adequately perfused tissue by a high inspiratory oxygen fraction (FIO2),3 and this is associated with increased bacterial eradication through oxidative killing by neutrophils;4 however, high oxygen tissue tension also increase neovascularization,5 collagen formation, and epithelialization.3
After 3 positive randomized trials,6–8 a high perioperative FIO2 (80%) was recommended to prevent postoperative wound infections.9 However, one of the largest and most recent trials, the PROXI trial,10 reported no reduction in surgical site infection and 30-day mortality was 4.4% versus 2.9% (P = 0.13) in patients given 80% and 30% oxygen, respectively. Additionally, a number of potential adverse effects have been associated with a high FIO2, including airway inflammation, atelectasis formation, arterial vasoconstriction, and reduced coronary bloodflow.11,12 It is not yet clear how (or whether) a high FIO2 might impact perioperative immune function.12–14
The aim of this post hoc follow-up study of the PROXI trial10 was to assess the association between a high perioperative oxygen fraction and long-term mortality in patients undergoing laparotomy.
The PROXI trial, and this follow-up study, were approved by the Danish Medicines Agency, the Danish Data Protection Agency, and the regional ethics committee (NCT00364741, De Videnskabsetiske Komiteer for Region Hovedstaden, Hillerød, Denmark).10,15 Written informed consent was obtained from all patients included in 14 Danish hospitals between October 8, 2006, and October 6, 2008. Patients were aged 18 years or older and scheduled for elective or emergency laparotomy. Exclusion criteria were surgery performed under general anesthesia within the preceding 30 days, chemotherapy for malignancy within 3 months of study inclusion, inability to give informed consent, and preoperative arterial oxygen saturation below 90% without supplemental oxygen.10,15 The participants were randomized centrally by the Copenhagen Trial Unit, an external department assuring allocation concealment and adequate generation of the allocation sequence.
The patients were randomized to either the 80% or the 30% oxygen group with stratification for: trial site, diabetes mellitus, elective or emergency surgery, and body mass index (<30 kg/m2 or ≥30 kg/m2). The trial protocol15 standardized several important aspects of perioperative care, including prophylactic antibiotics administration, epidural analgesia, temperature and glucose control, absence of preoperative oral bowel preparation, and standardized general anesthesia without nitrous oxide. Perioperative fluids were only administered to replace deficits or measured loss, aiming at a postoperative body weight increase of <1 kg. Blood loss was replaced 1:1 with IV colloids, and blood transfusion was initiated if blood loss exceeded 20 mL/kg.15
An FIO2 of 1.0 was used at induction of anesthesia until tracheal intubation and again immediately before tracheal extubation. After tracheal intubation, patients were given an FIO2 of 0.80 or 0.30 according to the randomization. The first 2 hours after tracheal extubation, the intervention (FIO2 of 0.80 or 0.30) was delivered through a nonrebreathing facemask with a reservoir (High Concentration Oxygen Mask, Intersurgical Ltd, Wokingham, UK) with a flow of 14 L of O2 and 2 L of air per minute in the 80% oxygen group and 2 L of O2 and 14 L of air per minute in the 30% oxygen group. The patients' lungs were ventilated to assure normocapnia.15 FIO2 was increased to ensure arterial oxygen saturation above 94% and arterial oxygen tension above 9 kPa (67.5 mm Hg). Two hours after surgery, supplemental oxygen was administrated only at the physician's discretion and according to usual clinical practice. The intervention was blinded to patients, surgeons, the staff on the wards, outcome assessors, statisticians, and, in addition, author blinding was used.15
The follow-up date was February 24, 2010. Vital status was obtained from the Danish Civil Registration System (www.cpr.dk), in which all Danish citizens are registered with a unique 10-digit number.16 We calculated time from anesthesia to death or follow-up date. If a patient emigrated in the follow-up period, the date of emigration was used for censoring. In the original protocol,15 the primary outcome measure was surgical site infection within 30 postoperative days and a secondary outcome was mortality within 30 days of surgery and anesthesia. However, the primary outcome for this follow-up study was all-cause mortality within the extended follow-up period. Cancer and noncancer surgery were defined according to the postoperative histological examination of the specimen obtained during surgery.
All primary survival analyses were performed using Kaplan-Meier statistics and unadjusted Cox proportional hazards model. A secondary adjusted analysis was performed for survival until end of follow-up17 using the following design variables as adjusting covariates: age, body mass index, daily smoking, emergency surgery, ASA physical status score, diabetes mellitus, cardiovascular disease other than hypertension, cancer surgery, perioperative blood transfusion, and trial site. A sensitivity analysis was performed where we excluded patients who did not receive the oxygen treatment per protocol, i.e., an FIO2 ≥0.60 for >1 hour (in the 30% oxygen group), an FIO2 <0.60 for >1 hour (in the 80% oxygen group), use of the oxygen mask <1 hour, or when no FIO2 data were available. Sample size was calculated for our original study to detect or reject a 33% relative risk reduction in the primary outcome of surgical site infection given an event rate of 16% in the 30% oxygen group, 5% type 1 error risk, 80% power, and 10% patient dropout rate.15 All intervention effect estimates were reported with 95% confidence limits and a 2-sided P < 0.05 was considered statistically significant. Analyses were performed using SAS for Windows, version 9.2 (SAS Institute, Inc., Cary, NC).
One thousand three hundred eighty-six patients were included in the modified intention-to-treat analysis of the PROXI trial.18 At follow-up, four patients were no longer Danish citizens, and vital status was obtained in the remaining 1382 patients (99.7%) after a median follow-up of 2.3 years (range 1.3 to 3.4 years). Patient characteristics were similar in the 2 groups (Table 1).
At follow-up, 159 of 685 patients (23.2%) had died in the 80% oxygen group compared to 128 of 701 patients (18.3%) patients assigned to 30% oxygen (unadjusted hazards ratio [HR], 1.30 [95% confidence interval [CI], 1.03 to 1.64], P = 0.03) (Fig. 1). The analysis adjusted for design variables showed a similar HR, 1.31 (95% CI, 1.03 to 1.66), P = 0.03 (Table 2). Increasing age, blood transfusion, cancer surgery, emergency surgery, and ASA physical status category III and IV were significantly associated with higher long-term mortality, whereas a high body mass index was associated with a significantly lower long-term mortality (Table 2), e.g., 148 of 667 patients (22.2%) with body mass index 18.5 to 24.9 kg/m2 were deceased at follow-up compared to 30 of 213 patients (14.1%) with body mass index ≥30 kg/m2. There were no significant differences in long-term mortality between the trial sites. One hundred fifty patients (10.8%) did not receive the oxygen treatment per protocol, but the HR for long-term mortality was virtually identical when these patients were excluded, 1.31 (95% CI, 1.02 to 1.67), P = 0.03 when comparing 80% with 30% oxygen.
We performed supplemental analyses for treatment effect heterogeneity, i.e., different effects of 80% oxygen in subgroups. Among patients undergoing cancer surgery, 118 of 352 patients (33.5%) died in the 80% oxygen group compared to 89 of 362 patients (24.6%) in the 30% oxygen group (unadjusted HR, 1.45 (95% CI, 1.10 to 1.90), P = 0.009) (Fig. 2). After noncancer surgery, long-term mortality was 41 of 333 patients (12.3%) in 80% oxygen group versus 39 of 339 patients (11.5%) in the 30% oxygen group (unadjusted HR, 1.06 [95% CI, 0.69 to 1.65], P = 0.79) (Fig. 3). There was no significant interaction (P = 0.24) between the intervention effect of 80% oxygen and whether cancer surgery or noncancer surgery was performed. Patients with a surgical site infection did not have significantly higher long-term mortality compared to patients without surgical site infection (61 of 272 patients, 22.4% versus 226 of 1114 patients, 20.3%, respectively, unadjusted HR, 1.12 [95% CI, 0.85 to 1.49], P = 0.43).
In this follow-up study of a randomized clinical trial comparing 80% oxygen with 30% oxygen during abdominal surgery, we found that a high FIO2 of 80% was associated with increased long-term mortality. The difference appeared to be statistically significant in patients undergoing cancer surgery but not in noncancer patients.
The primary strength of our study is the almost complete follow-up (99.7%) and the high validity of data concerning vital status in Denmark.16 No other trials have evaluated the direct association between supplemental oxygen and mortality beyond 30 days after surgery, that is, without the interference of other potentially influential gases especially nitrous oxide.8
Some study limitations must be mentioned. First, it must be emphasized that long-term mortality was not the primary outcome of our trial, and this follow-up study was performed to explore the safety of high perioperative FIO2 during abdominal surgery because an apparent substantially higher point-estimate of the 30-day mortality (e.g., a 50% mortality increase) was found in the 80% oxygen group. Our results can therefore generate new hypotheses, but they do not prove causality. Second, some patients in the 2 groups were given an oxygen fraction that was different from the allocated fraction. Seven percent of the patients in the 30% oxygen group needed an FIO2 ≥0.60 for >1 hour to keep arterial oxygen saturation above 94% in accordance with safety measures in clinical practice. In the 80% oxygen group, 2% of the patients received an FIO2 <0.60; however, the observed mortality HR was not altered when we excluded those patients who did not receive the oxygen treatment per protocol. Third, laparoscopic abdominal procedures were not included, and the results of this trial are thus only generalizable to a general surgical population undergoing laparotomy.
The observed difference in long-term mortality is difficult to explain and the following three aspects must be considered in the interpretation:
First, because a larger sample size is required to detect or reject a HR of 1.30, given the median survival times and follow-up, our finding may be considered a result of an “early” or “preliminary” analysis, which may be comparable to an interim-analysis in a larger trial. As such, it is well recognized that a more restrictive, and lower, significance level is needed to avoid spurious statistical significance (e.g., P < 0.001 for an interim-analysis halfway to the required sample size).19,20 Our result, exhibiting a P value of 0.03, may therefore be a type 1 error, because the P value is considerably higher than what would be required to stop a randomized trial for benefit at an interim-analysis.21,22 The ability to replicate study findings should always be considered, and it may be calculated that in this study there is only approximately 50% probability of finding a P value of 0.03 or less for increased long-term mortality with 80% oxygen, if another 1400 patients were studied with the same intervention effect.23 Furthermore, we recognize that this follow-up was not preplanned, but performed for safety reasons because a higher point-estimate of 30-day mortality was found in the 80% oxygen group. Further studies are required before an association between perioperative hyperoxia and long-term mortality is established beyond reasonable doubt.
The second aspect is imbalances between the groups, which should always be carefully evaluated in a randomized trial, however the numerous recorded baseline characteristics were very similar in the 2 groups, and the risk of an unknown imbalance is less with our stratified randomization and the relatively large number of patients.
The third reason for the observed difference may be a true adverse effect of a high oxygen fraction. Until now, 4544 patients have been included in the 10 trials investigating 80% versus 30% perioperative oxygen,6–8,10,24–29 and the reported 30-day mortality is overall 34 of 2772 patients (1.2%) versus 38 of 2799 patients (1.4%), respectively. A 3.5-year follow-up of the ENIGMA trial8 found no significant difference in long-term mortality (HR, 0.98; 95% CI, 0.80 to 1.20) in 1660 patients randomized to receive either 70% nitrous oxide in 30% oxygen or 80% oxygen in 20% nitrogen.30 The combination of the 2 interventions, 80% oxygen and nitrous oxide, however, only allows a conclusion that long-term mortality is not significantly different in patients receiving 80% oxygen compared to patients receiving 70% nitrous oxide. The pathophysiological rationale behind the ENIGMA trial suggested that nitrous oxide alone may be associated with increased long-term cardiovascular morbidity and mortality.31
It is nevertheless surprising to find a significantly increased mortality in our 80% oxygen group after 2.3 years. If there were a true difference, such a negative effect of 80% oxygen does not appear to be related to the immediate postoperative harm that may be related to very high FIO2 such as pulmonary atelectasis and respiratory failure. A possible intervention effect is more likely to occur through different mechanisms, specifically in cancer patients, because the majority of the observed differences occurred in this subgroup, although we recognize that there was a higher power to detect a difference with the higher overall mortality among cancer patients.
Anesthesia may have long-term effects on cancer recurrence,1 because numerous perioperative factors affect the clearing of tumor cells that remain in the body after otherwise curative surgery.32 Those factors include neovascularization, growth factors, and immunosuppression.32 Supplemental perioperative oxygen has a strong positive effect on neovascularization,3 whereas growth factor stimulation and the effect on local immunological factors are not fully understood.14,33 High levels of oxygen increase erythropoietin production, which is a potent cellular growth factor.33 In addition, supplemental oxygen promotes formation of reactive oxygen species,3,34 which may promote DNA damage.34 Neovascularization, erythropoietin, and oxidative stress may thus lead to growth of remaining tumor cells after otherwise curative surgery.
It must be noted though that most of the articles published in the experimental setting support a tumor-suppressive effect of oxygen,13,14,33,35 which further renders the finding of a higher mortality at the end of follow-up in the 80% oxygen group in our study controversial. A test of interaction between the intervention effect of 80% oxygen and whether cancer surgery or noncancer surgery was performed was not statistically significant. The lack of a statistically significant test of interaction may, however, have been due to lack of power of the test of interaction.
Other potentially adverse biological mechanisms of a high oxygen concentration could include lung damage caused by perioperative oxidative stress and airway inflammation, especially in patients with chronic obstructive lung disease.12,36 The cardiovascular system may be affected by perioperative arterial vasoconstriction,37 reduced coronary bloodflow,11 or oxidative stress and DNA damage34,38 leading to accelerated atherosclerosis or plaque rupture.12,36,38
At this stage, the main finding of the present study is not explained by a convincing mechanism, but it definitely does not support the contention that a high perioperative FIO2 is beneficial on long-term all-cause mortality. Further studies are required to evaluate the cause of death, when cancer recurrence and emergence of new or latent cancer will be of great relevance.
The PROXI trial was probably underpowered to detect well-known risk factors for death such as diabetes mellitus and current smoking. It is also noteworthy that increasing body mass index was associated with lower long-term mortality. An almost identical association between body mass index and 1-year mortality was found in a cohort study of 1064 patients undergoing major noncardiac surgery,39 and it is documented that obesity itself is not a risk factor for major postoperative complications during hospitalization.40 These apparently better outcomes for obese patients may be attributed to selection bias and confounding by indication with differences in the management of obese patients, and the amount of preoperative weight loss was not measured. In our trial, surgical site infection was not associated with a significantly higher long-term mortality, suggesting that most surgical site infections were not severe.41
Common indications for supplemental oxygen have been prevention of surgical wound infection and postoperative nausea and vomiting. Before the results of the PROXI trial, a statistically significant reduction of surgical site infection could be documented,9 but when the results of the PROXI trial are added, the potential benefit of supplemental oxygen to prevent surgical site infection is outweighed and a clinically relevant effect is yet to be demonstrated. The initially reported positive effect of supplemental oxygen on the incidence of postoperative nausea and vomiting was not confirmed in a meta-analysis.42
We conclude that administration of 80% oxygen during, and for 2 hours after abdominal surgery, compared to 30% oxygen, is associated with a significantly increased long-term all-cause mortality that appears to be statistically significant in patients undergoing cancer surgery but not in noncancer patients. Until a clinical benefit of 80% perioperative oxygen is well-documented, we recommend abstaining from administering FIO2 above what is needed to maintain sufficient arterial oxygen saturation.
Name: Christian S. Meyhoff, MD, PhD.
Contribution: The author helped design the study, conduct the study, analyze the data, and prepare the manuscript.
Attestation: Christian S. Meyhoff attests to the integrity of the original data and the analysis.
Name: Lars N. Jorgensen, MD, DMSc.
Contribution: The author helped design the study, analyze the data, and prepare the manuscript.
Name: Jørn Wetterslev, MD, PhD.
Contribution: The author helped design the study, analyze the data, and prepare the manuscript.
Name: Karl B. Christensen, PhD.
Contribution: The author helped analyze the data and prepare the manuscript.
Name: Lars S. Rasmussen, MD, PhD, DMSc.
Contribution: The author helped design the study, conduct the study, analyze the data, and prepare the manuscript.
Attestation: Lars S. Rasmussen attests to the integrity of the original data and the analysis.
This mansucript was handled by: Sorin J. Brull, MD, FCARCSI (Hon).
1. Sessler DI. Long-term consequences of anesthetic management. Anesthesiology 2009;111:1–4
2. Hopf HW, Hunt TK, West JM, Blomquist P, Goodson WH III, Jensen JA, Jonsson K, Paty PB, Rabkin JM, Upton RA, von SK, Whitney JD. Wound tissue oxygen tension predicts the risk of wound infection in surgical patients. Arch Surg 1997;132:997–1004
3. Hopf HW, Holm J. Hyperoxia and infection. Best Pract Res Clin Anaesthesiol 2008;22:553–69
4. Babior BM. Oxygen-dependent microbial killing by phagocytes (first of two parts). N Engl J Med 1978;298:659–68
5. Roy S, Khanna S, Nallu K, Hunt TK, Sen CK. Dermal wound healing is subject to redox control. Mol Ther 2006;13:211–20
6. Belda FJ, Aguilera L, García de la Asunción J, Alberti J, Vicente R, Ferrandiz L, Rodriguez R, Company R, Sessler DI, Aguilar G, Botello SG, Orti R. Supplemental perioperative oxygen and the risk of surgical wound infection: a randomized controlled trial. JAMA 2005;294:2035–42
7. Greif R, Akca O, Horn EP, Kurz A, Sessler DI. Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection. Outcomes Research group. N Engl J Med 2000;342:161–7
8. Myles PS, Leslie K, Chan MT, Forbes A, Paech MJ, Peyton P, Silbert BS, Pascoe E. Avoidance of nitrous oxide for patients undergoing major surgery: a randomized controlled trial. Anesthesiology 2007;107:221–31
9. Qadan M, Akca O, Mahid SS, Hornung CA, Polk HC Jr. Perioperative supplemental oxygen therapy and surgical site infection: a meta-analysis of randomized controlled trials. Arch Surg 2009;144:359–66
10. Meyhoff CS, Wetterslev J, Jorgensen LN, Henneberg SW, Hogdall C, Lundvall L, Svendsen PE, Mollerup H, Lunn TH, Simonsen I, Martinsen KR, Pulawska T, Bundgaard L, Bugge L, Hansen EG, Riber C, Gocht-Jensen P, Walker LR, Bendtsen A, Johansson G, Skovgaard N, Helto K, Poukinski A, Korshin A, Walli A, Bulut M, Carlsson PS, Rodt SA, Lundbech LB, Rask H, Buch N, Perdawid SK, Reza J, Jensen KV, Carlsen CG, Jensen FS, Rasmussen LS, PROXI Trial Group. Effect of high perioperative oxygen fraction on surgical site infection and pulmonary complications after abdominal surgery: the PROXI Randomized Clinical Trial. JAMA 2009;302:1543–50
11. Rothen HU. Oxygen: avoid too much of a good thing! Eur J Anaesthesiol 2010;27:493–4
12. Meyhoff CS, Staehr AK, Rasmussen LS. Rational use of oxygen in medical disease and anesthesia. Curr Opin Anaesthesiol 2012;25:363–70
13. Bitterman H. Bench-to-bedside review: oxygen as a drug. Crit Care 2009;13:205
14. Qadan M, Battista C, Gardner SA, Anderson G, Akca O, Polk HC Jr. Oxygen and surgical site infection: a study of underlying immunologic mechanisms. Anesthesiology 2010;113:369–77
15. Meyhoff CS, Wetterslev J, Jorgensen LN, Henneberg SW, Simonsen I, Pulawska T, Walker LR, Skovgaard N, Helto K, Gocht-Jensen P, Carlsson PS, Rask H, Karim S, Carlsen CG, Jensen FS, Rasmussen LS, PROXI Trial Group. Perioperative oxygen fraction—effect on surgical site infection and pulmonary complications after abdominal surgery: a randomized clinical trial. Rationale and design of the PROXI-Trial. Trials 2008;9:58
16. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263–8
17. International Conference on Harmonisation E9 Expert Working Group. ICH harmonised tripartite guideline: statistical principles for clinical trials. Stat Med 1999;18:1905–42
18. Fergusson D, Aaron SD, Guyatt G, Hebert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ 2002;325:652–4
19. Lan KK, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659–63
20. Ioannidis JP. Why most published research findings are false. PLoS Med 2005;2:e124
21. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol 2009;9:86
22. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008;61:64–75
23. Senn S. Letter to the Editor: a comment on replication, p-values and evidence. Stat Med 2002;21:2437–44
24. Gardella C, Goltra LB, Laschansky E, Drolette L, Magaret A, Chadwick HS, Eschenbach D. High-concentration supplemental perioperative oxygen to reduce the incidence of postcesarean surgical site infection: a randomized controlled trial. Obstet Gynecol 2008;112:545–52
25. Mayzler O, Weksler N, Domchik S, Klein M, Mizrahi S, Gurman GM. Does supplemental perioperative oxygen administration reduce the incidence of wound infection in elective colorectal surgery? Minerva Anestesiol 2005;71:21–5
26. Pryor KO, Fahey TJ III, Lien CA, Goldstein PA. Surgical site infection and the routine use of perioperative hyperoxia in a general surgical population: a randomized controlled trial. JAMA 2004;291:79–87
27. Anthony T, Murray BW, Sum-Ping JT, Lenkovsky F, Vornik VD, Parker BJ, McFarlin JE, Hartless K, Huerta S. Evaluating an evidence-based bundle for preventing surgical site infection: a randomized trial. Arch Surg 2011;146:263–9
28. Bickel A, Gurevits M, Vamos R, Ivry S, Eitan A. Perioperative hyperoxygenation and wound site infection following surgery for acute appendicitis: a randomized, prospective, controlled trial. Arch Surg 2011;146:464–70
29. Scifres CM, Leighton BL, Fogertey PJ, Macones GA, Stamilio DM. Supplemental oxygen for the prevention of postcesarean infectious morbidity: a randomized controlled trial. Am J Obstet Gynecol 2011;205:267–9
30. Leslie K, Myles PS, Chan MT, Forbes A, Paech MJ, Peyton P, Silbert BS, Williamson E. Nitrous oxide and long-term morbidity and mortality in the ENIGMA trial. Anesth Analg 2011;112:387–93
31. Myles PS, Leslie K, Silbert B, Paech MJ, Peyton P. A review of the risks and benefits of nitrous oxide in current anaesthetic practice. Anaesth Intensive Care 2004;32:165–72
32. Snyder GL, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth 2010;105:106–15
33. De Bels D, Corazza F, Germonpre P, Balestra C. The normobaric oxygen paradox: A novel way to administer oxygen as an adjuvant treatment for cancer? Med Hypotheses 2011;76:467–70
34. Tertil M, Jozkowicz A, Dulak J. Oxidative stress in tumor angiogenesis- therapeutic targets. Curr Pharm Des 2010;16:3877–94
35. Raa A, Stansberg C, Steen VM, Bjerkvig R, Reed RK, Stuhr LE. Hyperoxia retards growth and induces apoptosis and loss of glands and blood vessels in DMBA-induced rat mammary tumors. BMC Cancer 2007;7:23
36. Carpagnano GE, Kharitonov SA, Foschino-Barbaro MP, Resta O, Gramiccioni E, Barnes PJ. Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation. Thorax 2004;59:1016–9
37. Harten JM, Anderson KJ, Kinsella J, Higgins MJ. Normobaric hyperoxia reduces cardiac index in patients after coronary artery bypass surgery. J Cardiothorac Vasc Anesth 2005;19:173–5
38. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 2001;104:503–16
39. Monk TG, Saini V, Weldon BC, Sigl JC. Anesthetic management and one-year mortality after noncardiac surgery. Anesth Analg 2005;100:4–10
40. Dindo D, Muller MK, Weber M, Clavien PA. Obesity in general elective surgery. Lancet 2003;361:2032–5
41. Coello R, Charlett A, Wilson J, Ward V, Pearson A, Borriello P. Adverse impact of surgical site infections in English hospitals. J Hosp Infect 2005;60:93–103
42. Orhan-Sungur M, Kranke P, Sessler D, Apfel CC. Does supplemental oxygen reduce postoperative nausea and vomiting? A meta-analysis of randomized controlled trials. Anesth Analg 2008;106:1733–8
© 2012 International Anesthesia Research Society